RIPK1
ENSG00000137275
Target class
Kinase
Chromosome
6
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- Yes
- Target name
- RIPK1
- Gene name
- Receptor interacting serine/threonine kinase 1
- Gene symbol
- RIPK1
- Protein name
- Receptor-interacting serine/threonine-protein kinase 1 (EC 2.7.11.1) (Cell death protein RIP) (Receptor-interacting protein 1) (RIP-1)
- RIP
- RIP1
- RIP-1
- Gene biotype
- Protein coding
- Gene family
- Ripoptosome|Receptor interacting serine/threonine kinase family
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 37.69
- Tissue specificity (Gini)
- 0.281
- Tissue specificity (tau)
- 0.424
- KEGG gene identifiers
- hsa:8737
- Protein interaction confidence
- 0.904247
- Protein interaction partners
- 97
- R-HSA-140534
- R-HSA-168927
- R-HSA-1810476
- R-HSA-2562578
- R-HSA-3295583
- R-HSA-3371378
- R-HSA-5213460
- R-HSA-5218900
- R-HSA-5357786
- R-HSA-5357905
- R-HSA-5357956
- R-HSA-5675482
- R-HSA-5689880
- R-HSA-5689896
- R-HSA-69416
- R-HSA-75893
- R-HSA-9013957
- R-HSA-933543
- R-HSA-937041
- R-HSA-9679191
- R-HSA-9686347
- R-HSA-9692913
- R-HSA-9693928
- R-HSA-9920951
- End position
- 3115187
- Start position
- 3063824
- Chromosome
- 6
- Strand
- Forward
- Cytoplasm . Cell membrane .
- Cytosol
- Plasma membrane
- Tissue specificity (tau)
- 0.423555
- Expression inequality (Gini)
- 0.280909
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)
- 37.69
- Adipose - Subcutaneous
- 37.18
- Skin - Not Sun Exposed (Suprapubic)
- 36.57
- Spleen
- 35.95
- Small Intestine - Terminal Ileum
- 35.11
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)37.69
- Adipose - Subcutaneous37.18
- Skin - Not Sun Exposed (Suprapubic)36.57
- Spleen35.95
- Small Intestine - Terminal Ileum35.11
- Thyroid34.94
- Uterus34.61
- Bladder34.13
- Fallopian Tube32.89
- Nerve - Tibial32.24
- Lung32.09
- Artery - Tibial32.04
- Breast - Mammary Tissue31.98
- Cells - Cultured fibroblasts31.24
- Cervix - Endocervix31.1
- Colon - Sigmoid30.95
- Esophagus - Gastroesophageal Junction30.55
- Artery - Coronary30.37
- Adipose - Visceral (Omentum)30.3
- Esophagus - Muscularis29.92
- Vagina29.43
- Cervix - Ectocervix29.42
- Prostate29.06
- Esophagus - Mucosa27.97
- Colon - Transverse27.79
And 29 more, listed on the interactive page.
- GO:0006915
- GO:0006979
- GO:0007249
- GO:0010628
- GO:0032147
- GO:0032757
- GO:0032760
- GO:0033209
- GO:0034612
- GO:0035556
- GO:0043065
- GO:0043068
- GO:0043123
- GO:0043124
- GO:0045651
- GO:0045944
- GO:0046330
- GO:0050729
- GO:0060545
- GO:0062100
- GO:0070105
- GO:0070266
- GO:0071356
- GO:0097191
- GO:0097343
And 7 more, listed on the interactive page.
- GO:0005739
- GO:0005829
- GO:0005886
- GO:0010008
- GO:0031264
- GO:0032991
- GO:0043235
- GO:0097342
- GO:0004672
- GO:0004674
- GO:0005123
- GO:0005515
- GO:0031625
- GO:0042802
- GO:0042803
- GO:0044877
- GO:0070513
- GO:0106310
- GO:0120283
Related records
Trials (86)
- A Drug Interaction Study of LY3871801 in Healthy Participants
- A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19
- A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
- A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
- A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects
- A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects
- A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia
- A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)
- A Study of Carbon-14-Labelled [14C] LY3871801 in Healthy Male Participants
- A Study of LY3871801 in Healthy Asian and Non-Asian Participants
- A Study of LY3871801 in Healthy Participants
- A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)
- A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
- A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)
- A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)
- A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses
- A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
- A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis
- A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE)
Drugs (6)
- Eclitasertib
- Flizasertib
- GSK2982772 Receptor-interacting serine/threonine-protein kinase 1 inhibitor
- Ocadusertib
- Oditrasertib
- Ponatinib